Your browser is no longer supported. Please, upgrade your browser.
MCRB Seres Therapeutics, Inc. monthly Stock Chart
Seres Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.19 Insider Own8.86% Shs Outstand83.53M Perf Week-14.89%
Market Cap2.49B Forward P/E- EPS next Y-0.54 Insider Trans0.00% Shs Float83.16M Perf Month-2.71%
Income-89.70M PEG- EPS next Q-0.28 Inst Own88.60% Short Float5.72% Perf Quarter18.99%
Sales23.30M P/S106.95 EPS this Y48.90% Inst Trans27.20% Short Ratio6.45 Perf Half Y435.34%
Book/sh2.25 P/B13.06 EPS next Y50.90% ROA-51.20% Target Price37.50 Perf Year592.34%
Cash/sh3.51 P/C8.37 EPS next 5Y- ROE- 52W Range2.52 - 38.50 Perf YTD751.88%
Dividend- P/FCF- EPS past 5Y-21.10% ROI303.30% 52W High-23.66% Beta4.34
Dividend %- Quick Ratio6.70 Sales past 5Y- Gross Margin- 52W Low1066.27% ATR2.50
Employees108 Current Ratio6.70 Sales Q/Q-80.00% Oper. Margin- RSI (14)42.80 Volatility9.12% 7.45%
OptionableYes Debt/Eq0.13 EPS Q/Q-54.50% Profit Margin- Rel Volume0.87 Prev Close30.68
ShortableYes LT Debt/Eq0.13 EarningsNov 09 BMO Payout- Avg Volume737.72K Price29.39
Recom1.90 SMA20-10.56% SMA50-4.21% SMA200118.07% Volume641,487 Change-4.20%
Sep-18-20Downgrade Chardan Capital Markets Buy → Neutral $32.50 → $27.50
Aug-18-20Initiated Piper Sandler Overweight $40
Aug-11-20Upgrade Jefferies Hold → Buy $4 → $29
Aug-11-20Reiterated H.C. Wainwright Buy $8 → $41
Apr-30-19Initiated Jefferies Hold $7
Oct-22-18Initiated Chardan Capital Markets Buy $15
Oct-13-17Initiated Oppenheimer Outperform $19
Aug-04-17Reiterated H.C. Wainwright Buy $15 → $19
Feb-01-17Reiterated FBR & Co. Outperform $23 → $18
Aug-12-16Reiterated FBR Capital Outperform $43 → $23
Aug-01-16Reiterated H.C. Wainwright Buy $50 → $15
Aug-01-16Downgrade BofA/Merrill Buy → Neutral
Jul-29-16Resumed H.C. Wainwright Buy $50
Mar-30-16Initiated FBR Capital Outperform $40
Mar-03-16Initiated Guggenheim Buy
Jan-25-16Initiated H.C. Wainwright Buy $55
Oct-22-15Upgrade BofA/Merrill Neutral → Buy
Jul-22-15Initiated Canaccord Genuity Buy $50
Jul-21-15Initiated Leerink Partners Outperform
Jul-21-15Initiated Goldman Neutral
Nov-20-20 07:15AM  
Nov-19-20 07:00AM  
Nov-12-20 06:17AM  
Nov-11-20 09:04AM  
Nov-09-20 04:00PM  
Nov-06-20 07:00AM  
Nov-02-20 07:00AM  
Oct-22-20 07:00AM  
Oct-12-20 07:00AM  
Oct-01-20 01:00PM  
Sep-22-20 07:00AM  
Sep-14-20 07:00AM  
Sep-11-20 07:00AM  
Aug-21-20 02:24PM  
Aug-18-20 09:48AM  
Aug-17-20 04:15PM  
Aug-13-20 06:31PM  
Aug-12-20 09:39PM  
Aug-11-20 06:38PM  
Aug-10-20 03:52PM  
Aug-07-20 08:55AM  
Jul-28-20 12:33PM  
Jul-08-20 10:06AM  
Jul-07-20 08:56AM  
Jun-25-20 11:23AM  
Jun-22-20 07:00AM  
Jun-07-20 06:24PM  
Jun-02-20 04:00PM  
May-31-20 08:27PM  
May-28-20 08:00AM  
May-18-20 07:00AM  
May-11-20 02:10AM  
May-09-20 01:31PM  
May-07-20 10:25AM  
Apr-30-20 12:33PM  
Apr-06-20 07:00AM  
Mar-30-20 07:00AM  
Mar-23-20 07:00AM  
Mar-19-20 06:56PM  
Mar-15-20 03:00PM  
Mar-13-20 07:00AM  
Mar-04-20 08:56AM  
Mar-02-20 08:15AM  
Feb-25-20 04:00PM  
Jan-17-20 08:26AM  
Dec-20-19 05:04PM  
Dec-19-19 08:00AM  
Dec-16-19 07:00AM  
Nov-18-19 12:21PM  
Nov-14-19 07:00AM  
Nov-05-19 08:35AM  
Oct-31-19 04:00PM  
Sep-19-19 03:26PM  
Aug-22-19 10:01AM  
Aug-14-19 12:33PM  
Aug-08-19 06:38AM  
Aug-06-19 04:23PM  
Jul-25-19 10:34AM  
Jun-22-19 09:05AM  
Jun-19-19 07:00AM  
Jun-17-19 09:37AM  
Jun-13-19 09:23PM  
Jun-12-19 04:07PM  
May-29-19 04:00PM  
May-08-19 01:29AM  
May-02-19 09:25AM  
Apr-29-19 04:00PM  
Apr-26-19 04:26PM  
Apr-02-19 08:00AM  
Mar-23-19 08:10AM  
Mar-13-19 08:45AM  
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs that are designed to restore health by repairing the function of a dysbiotic microbiome. The company's lead product candidate is the SER-109, which is in Phase III clinical development for preventing recurrence of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb study treat ulcerative colitis; SER-401, a microbiome therapeutic candidate, which is in Phase Ib study for use with checkpoint inhibitors in patients with metastatic melanoma; and SER-301, an Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease. In addition, the company engages in the development of SER-262, to treat an initial recurrence of CDI; and SER-155 to modulate the microbiome and dysbiosis in patients following allogeneic hematopoietic stem cell transplants. The company has license and collaboration agreement with Nestec Ltd. and Memorial Sloan Kettering Cancer Center, as well as collaboration with AstraZeneca. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.